ƽÌØÎå²»ÖÐ

Endocrinology Presentations

Menopause and Andropause: Treatable Conditions?

David Morris has been an Associate Professor of Medicine and Gynecology at ƽÌØÎå²»ÖÐ since 1987. Before this he underwent a long training in Internal Medicine and Endocrinology having graduated originally from Cambridge University in 1970. He was involved in the development of pelvic ultrasonography for the diagnosis of female reproductive disorders. In Canada for 26 years with a primary responsibility in Reproductive Medicine. He helped found the ƽÌØÎå²»ÖÐ Reproductive Centre (now the MUHC Reproductive Centre). His major Research interest has been the relationship between metabolic disease and infertility in men and women (Polycystic Ovary Syndrome) and its treatment. Other areas include the treatment of Premature Ovarian Failure and the metabolic disturbances associated with malignant disease.

Learning Objectives:

1. Understand the important health impacts of reproductive aging on health
2. 'Demythologize’ reproductive aging and analyze the true impacts of the changing endocrine environment on health
3. Discuss the options for treatment – both symptomatic and protective
4. Be able to better discuss these options with their patients

Osteoporosis: The Era of Biologicals

Dr. Vautour is originally from the Maritimes. She obtained her medical degree from the University of Toronto in 1992. After medical school, she came to ƽÌØÎå²»ÖÐ where she completed her internal medicine residency and her endocrinology fellowship. Following this, she completed additional training specializing in bone disorders with Drs. Kremer, Goltzman and Karaplis. In 1998, she came on staff as a physician in the Division of Endocrinology and an associate professor of medicine at the ƽÌØÎå²»ÖÐ Health Centre. Taking a leave of absence from ƽÌØÎå²»ÖÐ, she then left for the Mayo Clinic in Rochester Minnesota where she completed additional epidemiology research training in osteoporosis under the supervision of Dr. L. Joseph Melton. She later obtained a Master’s in epidemiology from ƽÌØÎå²»ÖÐ in 2008, while working with the CaMos Database. She was the residency training Program Director for ƽÌØÎå²»ÖÐ Endocrinology from 1998 until 2005. She currently practices endocrinology at the MUHC where her clinical and teaching interests are in the field of mineral and bone disorders.

Learning Objectives:

1. Understand the properties and the role of biologicals in the management of osteoporosis and prevention of fractures
2. Understand some of the limitations and adverse events associated with biologicals
3. Appreciate that there are optimal sequences of individual agents in treating osteoporosis
4. Identify clinical situations for starting these therapies

Lipid Management: The Era of Biologicals

Mark Sherman is a native Montrealer who did his medical school at ƽÌØÎå²»ÖÐ. He trained in Internal Medicine and was Chief Medical Resident at the Jewish General Hospital, and Endocrinology and Metabolism at ƽÌØÎå²»ÖÐ. He followed this with an apprenticeship in the Lipid Clinics at the Royal Victoria Hospital and has been the Director of the Lipid Clinic since 1993. He is a certified Lipidologist, a Fellow of the National Lipid Association, and has been involved in clinical trials with Diabetes and Lipid-lowering medications for close to 30 years. Currently, he is Associate Professor of Medicine, ƽÌØÎå²»ÖÐ, the Director of the Metabolic Health Centre at the MUHC, and sees patients at the MUHC as well as at the LMC Endocrinology clinics. He collaborates in Clinical projects and has published with colleagues in Endocrinology, Cardiology, Epidemiology, Sleep Medicine and Hepatology.

Learning Objectives:

1. Understand what a "biological is"
2. Recognize basic lipid metabolic pathways
3. Interpret the evidence for current and upcoming biologicals in lipid management
4. Know the roles of biologicals in patient management
5. Know how to access the meds / who to consult

My Patient is Obese. Is it Hormonal?

Dr Michael Tsoukas is an Assistant Professor of Medicine, Division of Endocrinology of the MUHC. He completed his residency in medicine at Tuft’s University in Boston and pursued a post-graduate research fellowship in diabetes and obesity at Harvard University (Beth Israel Deaconess Medical Center), with a focus on GLP-1 receptor pharmacotherapy, brain signaling, and enterohormone treatments. Further training involved pathophysiological regulation of novel molecules such as SGLT-2 inhibitors and GLP-1 receptor agonists important in energy homeostasis, diabetes, and obesity. He has authored over 40 articles in peer-reviewed journals, chapters, and abstracts. Recently, he was selected to be an Executive Member of the Professional Section for Diabetes Canada. Concurrently, he is also involved in training future generations as the Residency Director for Endocrinology at the Montreal General Hospital.

Learning Objectives:

1. Provide an overview of the obesity epidemic and its role as a chronic disease
2. Discuss etiologies of obesity and potential treatment targets
3. Introduce national obesity guidelines, including bias and language
4. Describe emerging pharmacotherapy and surgical options in Canada

Thyroid Disease for the Family Physician

Dr. Pancer has been on staff in the Division of Endocrinology at the Jewish General Hospital since october 2020. She earned her medical degree at the Université de Montréal and completed her Internal Medicine residency and Endocrinology subspecialty training at ƽÌØÎå²»ÖÐ. She pursued additional training in women's health at Women's College Hospital, affiliated with the University of Toronto.

Ìý

Ìý

Learning Objectives:

1. Identify various causes of persistent hypothyroidism in spite of levothyroxine dose adjustmentÌý
2. Initiate an appropriate work-up for thyrotoxicosis
3. Determine high-risk clinical and radiologic features of thyroid nodules

2020 Diabetes Canada Guideline

Dr. Tina Kader is an endocrinologist and certified diabetes educator. She completed her endocrinology and internal medicine training at the Jewish General Hospital and ƽÌØÎå²»ÖÐ, and has been a staff endocrinologist at the JGH since 1992. Dr. Kader has been a member of the Executive Committee of Diabetes Canada (formerly the Canadian Diabetes Association) since 2003. Dr. Kader delivers approximately 50 lectures a year, nationally and internationally, and her research interests include diabetes and pregnancy. She is a Fellow of the Royal College of Physicians and Surgeons of Canada.

Learning Objectives:

1. Understand where oral agents fit in for diabetes
2. Understand vascular protection for diabetes and benefit of newer agents of cardiorenal protection
3. Understand how often to screen for complications